Cancer chemotherapy in the older patient: What the medical oncologist needs to knew

Cancer

Volumn 80, Issue 7, 1997, Pages 1317-1322

  Balducci, Lodovico ^a,b   Extermann, Martine ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Aging; Cancer; Chemotherapy; Elderly

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTARABINE; DACARBAZINE; EPIPODOPHYLLOTOXIN; FLUDARABINE; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOMYCIN C; TAXANE DERIVATIVE; VINCA ALKALOID;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANTIBIOTIC PROPHYLAXIS; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

AGED; AGING; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE; GENES, MDR; GERIATRIC ASSESSMENT; HUMANS; NEOPLASMS;

EID: 0030924516     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971001)80:7<1317::AID-CNCR18>3.0.CO;2-A     Document Type: Review

References (51)

1. Cova D, Beretta G, Balducci L. Cancer chemotherapy in the older patient. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. In press.
2. Kimmik G, Fleming R, Muss H, Balducci L. Cancer chemotherapy in older adults: a tolerability perspective. Drugs Aging 1997;10:34-49.
3. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997;13:169-84.
4. Moscow JA, Schneider E, Cowan KH. Multidrug resistance. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers. Annual 16. Amsterdam: Elsevier Science BV, 1996:111-31.
5. Rockwell O, Hughes CS, Kennedy KA. Effect of host age on microenvironmental heterogeneity and efficacy of combined modality therapy in solid tumors. Int J Radiat Oncol Biol Phys 1991;20:259-63.
6. Reed JC. BCL-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995;9:450-73.
7. Balducci L, Ballester O. Non-Hodgkin's lymphoma in the elderly. Cancer Causes Control JMCC, 1996;5 (Suppl 3) 5-12.
8. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993;329:690-4.
9. Ershler WL. Age-related changes in tumor growth in experimental models. In Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. In press.
10. Valentinis B, Silvestrini R, Daidone MG, et al. 3H-thymidine labeling index, hormone receptors and ploidy in breast cancer from elderly patients. Breast Cancer Res Treat 1991;20: 19-24.
11. Balducci L, Wallace C, Khansur T, et al. Nutrition, cancer and aging: an annotated review. J Am Geriatr Soc 1986;34: 127-36.
12. Extermann M. Acute leukemia in the older patient. Clin Geriatr Med 1997;13:227-44.
13. O'Reilly S, Connors JM, Macpherson N, et al. Malignant lymphomas in the elderly. Clin Geriatr Med 1997;13: 251-64.
14. Thigpen JT. Ovarian cancer in the older patient. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. In press.
15. Duthie E. Functional changes of aging. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. In press.
16. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer. The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1406-14.
17. Burkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994;33:493-6.
18. Yamamoto N, Tamura T, Maerla M, et al. The influence of aging on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 1995;36:102-6.
19. Cohen HJ. Principles of treatment applied to medical oncology: an overview. Semin Oncol 1995;22(Suppl 1):1-3.
20. Lipschitz DA, Udupa KB. Age and the hematopoietic system. J Am Geriatr Soc 1986;34:448-54.
21. Lipschitz DA. Age-related decline in hematopoietic reserve capacity. Semin Oncol 1995;22 (Suppl 1):3-6.
22. Rothstein G. Hematopoiesis in the aged: a model of hematopoietic dysregulation? Blood 1993;82:2601-4.
23. Chatta GS, Price TH, Allen RC, et al. Effects of "in vivo" recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994;84:2923-9.
24. Beggs CB, Carbone PP. Clinical trials and drug toxicity in the elderly. Cancer 1979;52:1986-92.
25. Buchner T. Acute leukemia in the elderly. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. In press.
26. Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-26.
27. Brower M, Asbury R, Kramer Z, et al. Adjuvant chemotherapy of colorectal cancer in the elderly. Population-based experience. Proc Am Soc Clin Oncol 1993;12:195.
28. Doroshow JH. Anthracyclines and anthracendiones. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy. Philadelphia: Lippincott-Raven, 1996:409-34.
29. Vn Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
30. MacDonald DR. Neurotoxicity of chemotherapeutic agents. In: Perry MC, editor. The chemotherapy source book. Baltimore: Williams & Wilkins, 1992:666-79.
31. Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Cancer 1984;54:1269-75.
32. Rubin EH, Andersen JW, Berg DT, et al. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992;10:948-53.
33. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995;21:33-64.
34. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994;12: 2121-5.
35. Gallo JJ, Stanley L, Zack AE, Reichel W. Multidimensional assessment of the older patient. In: Reichel W, editor. Care of the elderly. Baltimore: Williams & Wilkins, 1995:15-30.
36. Waller DG, Fleming JS, Ramsay B, et al. The accuracy of creatinine clearance with and without urine collection as a measure of glomerular nitration rate. Postgrad Med 7 1991; 67:42-6.
37. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
38. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9.
39. Zagonel V, Pinto A, Monfardini S. Strategies to prevent chemotherapy-related toxicity in the older person. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. In press.
40. Schank W, Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older patients. J Am Geriatr Soc 1992;40:51-4.
41. de Campos E, Radford J, Steward W, et al. Clinical and "in vitro" effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small cell lung cancer. J Clin Oncol 1995;13:1623-31.
42. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126:673-81.
43. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992;10:117-27.
44. Jackson DV, Wells HB, Atkins JN, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988;84: 1016-22.
45. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin and cotrimoxazole for infection prophylaxis in acute leukemia. Am J Med 1988;84:847-54.
46. Stewart DJ, Evans WK, Shepherd FA, et al. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 1997;15:1897-905.
47. Uziely B, Gabizon A, Jeffers S, et al. Liposomal doxorubicin (doxil): antitumor activity and unique toxicities during two complementary phase I studies. Proc Am Soc Clin Oncol 1995;14:483.
48. Conroy T, Etienne PL, Adenis A, et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol 1996;14:164-70.
49. Hertel LW, Broder GB, Croin JS, et al. evaluation of antitumor activity of Gemcitabine. Cancer Res 1990;50:4417-22.
50. Extermann M, Balducci L. Issues related to clinical research in older cancer patients. In: Balducci L, Lyman GK, Ershler WB, editors. Comprehensive geriatric oncology. In press.
51. Pearlman DN, Branch LG, Ozminkowski RJ, et al. Transitions in health care use and expenditures among frail older adults. J Am Geriatr Soc 1997;45:550-7.